These innovative agents represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://loriebmm163721.suomiblog.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-54811403